Claim Substantiation: What the FTC and Your Audience Actually Require

The Federal Trade Commission's substantiation doctrine has been part of advertising law since the 1970s, formalized in the FTC Policy Statement Regarding Advertising Substantiation (1983). Its core principle is straightforward: before making an objective claim about a product or service, advertisers must have a reasonable basis for that claim. For most efficacy claims — health outcomes, performance data, comparative superiority — "reasonable basis" means "competent and reliable scientific evidence."

What makes this standard practically significant is not the legal exposure it creates, though the FTC's enforcement record (including $5 billion against Facebook in 2019 for privacy claims and hundreds of millions against health supplement marketers) demonstrates that exposure is real. What matters for professional writers is that the substantiation requirement defines the same bar that any expert reader applies to any claim in any professional document. The FTC codified into law what scientists, analysts, journalists, and sophisticated readers had always practiced: claims that cannot be supported to the substantiation standard are claims that expert readers do not believe.

The Substantiation Standard in Plain Terms

The FTC does not define "competent and reliable scientific evidence" in a single regulation. The standard is applied contextually through enforcement actions and guidance documents. The FTC's 2009 Guides Concerning the Use of Endorsements and Testimonials, significantly updated in 2023, and the FTC's 2012 .com Disclosures guidance provide the most current articulation of how the standard operates in practice.

The core elements of competent and reliable scientific evidence, as applied by the FTC and interpreted in enforcement actions and federal court decisions, are:

• Controlled testing — evidence from studies that include appropriate control conditions, not simply observed outcomes without comparison
• Conducted by experts — research performed by researchers with relevant expertise in the subject matter
• In an objective manner — without researcher financial conflicts that could distort design or reporting
• Generally accepted methodology — using study designs and statistical methods recognized as appropriate in the relevant field

The FTC applies this standard to advertising claims made to consumers. For claims made in professional documents — investor presentations, whitepapers, regulatory submissions, press releases that will be read by analysts — the evidentiary expectation is the same or higher, because the audience is more capable of identifying unsubstantiated claims and more likely to penalize them.

How Claim Types Determine the Substantiation Burden

Not every claim carries the same substantiation burden. The FTC distinguishes between types of claims in ways that professional writers can use to calibrate their evidence requirements:

Objective efficacy claims — claims that a product or service produces a specific measurable outcome — carry the highest substantiation burden. "Reduces systolic blood pressure by 10 mmHg" requires clinical evidence. "Increases sales conversion by 23 percent" requires controlled testing with appropriate methodology. "Cuts processing time in half" requires documented benchmarks.

Comparative claims — claims that one product or service outperforms another — require both evidence of the claimed advantage and evidence that the comparison is fair and representative. A comparison that cherry-picks the metric most favorable to the advertised product, or that compares against an unrepresentative competitor condition, fails the substantiation standard regardless of whether the underlying data is technically accurate.

Testimonials and endorsements — claims presented through the voice of a satisfied customer or expert — are governed by disclosure requirements under the FTC's 2023 updated guides. Material connections between endorsers and advertisers must be disclosed; testimonial results must be representative of typical results or clearly qualified as atypical.

Subjective claims and puffery — "world-class service," "industry-leading quality," "the best in the business" — are not subject to the substantiation doctrine because they do not make objective factual assertions. The legal protection for puffery is real, but the professional writing problem is that puffery has no persuasive value with expert audiences who have learned to discount it.

The Writing Patterns That Signal Unsubstantiated Claims

Expert readers identify unsubstantiated claims through specific writing patterns that appear in professional documents across industries. Understanding these patterns is essential for writers producing documents that will be reviewed by analysts, regulators, or technical experts.

Passive voice for source attribution — "It has been shown that..." or "Research demonstrates..." without a citation is a pattern that immediately signals to expert readers that the underlying source may not say what the sentence implies. Passive attribution allows writers to imply that robust evidence exists without specifying what that evidence is. Expert readers are trained to look for citations; a passive attribution without one is a red flag.

Relative comparisons without baselines — "40 percent faster," "twice as effective," "significantly better outcomes" — require a denominator that these formulations do not supply. Forty percent faster than what? Twice as effective as which alternative? "Significantly" in casual usage is not the same as "statistically significant" in a scientific context. Expert readers know this and will probe relative comparisons for the baselines they omit.

"Studies show" without citation — this construction implies a body of research supporting the claim while providing no way to evaluate the quality or relevance of that research. A single industry-sponsored study with a convenience sample and no control group technically satisfies "studies show" while providing essentially no substantiation. Expert readers treat "studies show" as a marker for further investigation, not as a trust signal.

Extrapolation beyond study conditions — citing a study conducted in one population, context, or product formulation as evidence for a claim about a different population, context, or formulation. FDA drug advertising standards specifically prohibit this extrapolation in promotional materials. Expert readers in most fields recognize it as a substantiation gap.

FDA Standards for Drug Advertising and What They Teach

FDA regulation of prescription drug advertising under 21 CFR Part 202 applies specifically to drug promotional materials. Its principles for what constitutes adequate evidence — and what constitutes misleading claims — extend well beyond pharmaceutical advertising and offer a model for professional claim-making in any technical domain.

The FDA's "fair balance" requirement states that promotional materials must present risks and benefits in a balanced way, with risks presented with comparable prominence to benefits. In practice, this means that a professional document making a strong positive claim should address the conditions, limitations, and counterevidence that qualify that claim — not in fine print, but with proportionate emphasis.

The FDA's "substantial evidence" standard for drug efficacy claims requires at least two adequate and well-controlled clinical trials producing consistent results. This standard is considerably more demanding than the FTC's general substantiation standard, but it defines the evidentiary bar that technical experts in clinical contexts will apply when reading claims about clinical outcomes regardless of who made them.

Professional Documents That Require Claim Discipline

The substantiation standard applies beyond advertising in any professional document context where claims are made to audiences capable of evaluating them:

Investor presentations and prospectuses — the SEC's prohibition on materially misleading statements in securities offerings (Rule 10b-5 under the Exchange Act) encompasses claims about product performance, market size, and competitive position that are not substantiated. Investment analysts reviewing these documents apply substantiation discipline as standard practice.

Regulatory submissions — claims made to regulatory agencies about product safety, efficacy, or compliance must meet the agency's evidentiary standard for the claim type. The FDA's pre-market notification process, the EPA's registration requirements for pesticides, and the FCC's equipment authorization process all require substantiation of specific claims as a condition of approval.

Academic and scientific publications — peer review is fundamentally a claim-substantiation process. Reviewers assess whether the data presented actually supports the conclusions drawn, whether the study design is appropriate to the claims, and whether the statistical analysis is correctly applied. The same criteria apply to whitepapers, research briefs, and technical reports read by scientific or technical audiences.

Press releases and media coverage — journalists who cover technical topics — health, finance, technology, policy — apply substantiation discipline when they can. A press release making strong efficacy claims will attract scrutiny from specialist reporters who know what "competent and reliable scientific evidence" looks like. A press release that cannot sustain that scrutiny produces coverage that contradicts or qualifies the claims, which is worse than no coverage.

Writing Claims That Satisfy Both Compliance and Credibility

The goal of claim substantiation in professional writing is not simply to avoid regulatory enforcement. It is to write in a way that expert readers — who are also your most important readers — find credible. A document that survives FTC scrutiny but fails the expert reader test has satisfied the legal standard without achieving the communication goal.

The practical approach is to write claims from the evidence rather than toward it. Start with what you can actually demonstrate — the specific study, the specific data set, the specific conditions under which the observed outcome occurred — and state the claim in the terms the evidence supports. Then decide whether additional evidence is needed to support the broader claim you want to make, or whether the narrower, evidence-supported claim is the one that belongs in the document.

This approach produces documents that are both compliant and credible, because both compliance and credibility require the same underlying discipline: knowing what the evidence actually shows, stating it accurately, and not implying more than the evidence supports.